UCB’s Vimpat Falters In Diabetic Pain
This article was originally published in The Pink Sheet Daily
Executive Summary
Neuropathy filing is "not approvable" at FDA, but seizure indication is on track, firm says.
You may also be interested in...
UCB Takes Back EU Try With Vimpat
Withdrawal follows July “not approvable” letter in diabetic pain.
UCB Takes Back EU Try With Vimpat
Withdrawal follows July “not approvable” letter in diabetic pain.
UCB’s Keppra XR Wins FDA Approval
Extended-release tabs set to beat Keppra generics to pharmacy shelves.